CARM1 and cancer: In 2020, a series of cyclic bis(2-bromobenzylidene) analogs were developed as dual inhibitors of CARM1 and CBP/p300, inducing apoptosis in various cancer cell lines, including MCF7, NB4, U937 and SH-SY5Y106.